Ezetimibe and simvastatin for the prevention of cardiovascular events in predialysis chronic kidney disease patients: a review

References

• SarnakMJLeveyASSchoolwerthACKidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and PreventionHypertension20034251050106514604997
   PubMed Web of Science ®Google Scholar
• ShulmanNBFordCEHallWDPrognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative GroupHypertension198913Suppl 5I80I932490833
   PubMedGoogle Scholar
• FoleyRNCollinsAJEnd-stage renal disease in the United States: an update from the United States Renal Data SystemJ Am Soc Nephrol200718102644264817656472
   PubMed Web of Science ®Google Scholar
• BaigentCKeechAKearneyPMEfficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statinsLancet200536694931267127816214597
   PubMed Web of Science ®Google Scholar
• ThavendiranathanPBagaiABrookhartMAChoudhryNKPrimary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trialsArch Intern Med2006166212307231317130382
   PubMedGoogle Scholar
• Heart Protection Study Collaborative GroupMRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trialLancet2002360932672212114036
   PubMed Web of Science ®Google Scholar
• TonelliMMoyeLSacksFMKiberdBCurhanGPravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiencyAnn Intern Med200313829810412529091
   PubMed Web of Science ®Google Scholar
• WannerCKraneVMärzWAtorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysisN Engl J Med2005353323824816034009
   PubMed Web of Science ®Google Scholar
• FellstromBCJardineAGSchmiederRERosuvastatin and cardiovascular events in patients undergoing hemodialysisN Engl J Med2009360141395140719332456
   PubMed Web of Science ®Google Scholar
• HerzogCAMangrumJMPassmanRSudden cardiac death and dialysis patientsSemin Dial200821430030718627568
   PubMed Web of Science ®Google Scholar
• GuérinAPPannierBMarchaisSJLondonGMArterial structure and function in end-stage renal diseaseCurr Hypertens Rep200810210711118474176
   PubMed Web of Science ®Google Scholar
• VaziriNDDyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequencesAm J Physiol Renal Physiol20062902F262F27216403839
   PubMed Web of Science ®Google Scholar
• HarperCRJacobsonTAManaging dyslipidemia in chronic kidney diseaseJ Am Coll Cardiol200851252375238418565393
   PubMed Web of Science ®Google Scholar
• KalaitzidisRGElisafMSThe role of statins in chronic kidney diseaseAm J Nephrol201134319520221791915
   PubMed Web of Science ®Google Scholar
• ChmielewskiMCarreroJJNordforsLLindholmBStenvinkelPLipid disorders in chronic kidney disease: reverse epidemiology and therapeutic approachJ Nephrol200821563564418949717
   PubMed Web of Science ®Google Scholar
• O’NealDLeePMurphyBBestJLow-density lipoprotein particle size distribution in end-stage renal disease treated with hemodialysis or peritoneal dialysisAm J Kidney Dis199627184918546142
   PubMed Web of Science ®Google Scholar
• van HeekMFarleyCComptonDSHoosLMSmith-TorhanADavisHREzetimibe potently inhibits cholesterol absorption but does not affect acute hepatic or intestinal cholesterol synthesis in ratsBr J Pharmacol200313881459146412721101
   PubMed Web of Science ®Google Scholar
• LandrayMBaigentCLeaperCThe second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKDAm J Kidney Dis200647338539516490616
   PubMed Web of Science ®Google Scholar
• PearsonTBallantyneCSiskCShahAVeltriEMaccubbinDComparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levelsAm J Cardiol200799121706171317560879
   PubMed Web of Science ®Google Scholar
• RosseboABPedersenTRBomanKIntensive lipid lowering with simvastatin and ezetimibe in aortic stenosisN Engl J Med2008359131343135618765433
   PubMed Web of Science ®Google Scholar
• KasteleinJJAkdimFStroesESSimvastatin with or without ezetimibe in familial hypercholesterolemiaN Engl J Med2008358141431144318376000
   PubMed Web of Science ®Google Scholar
• BotsMLHoesAWKoudstaalPJHofmanAGrobbeeDECommon carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam StudyCirculation1997965143214379315528
   PubMed Web of Science ®Google Scholar
• AmarencoPLabreucheJLavalleePTouboulPJStatins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysisStroke200435122902290915514180
   PubMed Web of Science ®Google Scholar
• StrazzulloPKerrySMBarbatoAVersieroMD’EliaLCappuccioFPDo statins reduce blood pressure? A meta-analysis of randomized, controlled trialsHypertension200749479279817309949
   PubMed Web of Science ®Google Scholar
• SchönbeckULibbyPInflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents?Circulation200410921 Suppl 1II18II2615173059
   PubMed Web of Science ®Google Scholar
• CannonCPGiuglianoRPBlazingMARationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromesAm Heart J2008156582683219061694
   PubMed Web of Science ®Google Scholar
• BaigentCLandrayMJReithCThe effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trialLancet201137797842181219221663949
   PubMed Web of Science ®Google Scholar
• BaigentCBlackwellLEmbersonJEfficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trialsLancet201037697531670168121067804
   PubMed Web of Science ®Google Scholar
• CannonCPSteinbergBAMurphySAMegaJLBraunwaldEMeta- analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapyJ Am Coll Cardiol200648343844516875966
   PubMed Web of Science ®Google Scholar
• LaRosaJCGrundySMWatersDDIntensive lipid lowering with atorvastatin in patients with stable coronary diseaseN Engl J Med2005352141425143515755765
   PubMed Web of Science ®Google Scholar
• PedersenTRFaergemanOKasteleinJJHigh-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trialJAMA2005294192437244516287954
   PubMed Web of Science ®Google Scholar
• ArmitageJThe safety of statins in clinical practiceLancet200737096011781179017559928
   PubMed Web of Science ®Google Scholar
• DavidsonMHMcGarryTBettisREzetimibe coadministered with simvastatin in patients with primary hypercholesterolemiaJ Am Coll Cardiol200240122125213412505224
   PubMed Web of Science ®Google Scholar
• FoleyRNParfreyPSSarnakMJClinical epidemiology of cardiovascular disease in chronic renal diseaseAm J Kidney Dis1998325 Suppl 3S112S1199820470
   PubMed Web of Science ®Google Scholar
• AgarwalREffects of statins on renal functionAm J Cardiol200697574875516490450
   PubMed Web of Science ®Google Scholar
• AbbateMZojaCCornaDCapitanioMBertaniTRemuzziGIn progressive nephropathies, overload of tubular cells with filtered proteins translates glomerular permeability dysfunction into cellular signals of interstitial inflammationJ Am Soc Nephrol199897121312249644631
   PubMed Web of Science ®Google Scholar